Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment
Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment
复制标题
既往骨质疏松症治疗持续时间对罗莫佐单抗治疗效果的影响
DOI：
10.1007/s00198-021-06261-2
复制
发表时间：
2022
影响因子：
4
通讯作者：
Y. Kato
中科院分区：
文献类型：
--
作者：
A. Tominaga;K. Wada;K. Okazaki;H. Nishi;Y. Terayama;Y. Kodama;Y. Kato
romosozumab的效果受既往骨质疏松症治疗的影响。在这里，我们表明，就在romosozumab之前的先前治疗的持续时间影响romosozumab的治疗效果。使用地舒单抗和口服双膦酸盐超过1年衰减romosozumab.IntroductionAs抗sclerostin抗体的效果，romosozumab抑制骨吸收和刺激骨形成。我们调查了12个月的romosozumab治疗的有效性是否取决于先前治疗的持续时间与特立帕鲁肽，狄诺塞单抗，或口服bisphosphonates.MethodsIn总，259骨质疏松症患者接受皮下注射romosozumab（210毫克），每4周在2019年和2020年。本研究设计为前后比较。研究终点为romosozumab治疗12个月后骨矿物质密度（BMD）的百分比变化。根据在开始romosozumab之前的先前治疗的类型和持续时间，将患者分为以下七组：非既往治疗组，相对于特立帕鲁肽使用1年或少于/超过1年的变化，相对于地舒单抗使用1年或少于/超过1年的变化，和改变口服双膦酸盐使用1年或更少/超过1年。罗莫珠单抗治疗的持续时间与治疗时间无明显关系（P> 0.05）。相比之下，既往地舒单抗或口服双膦酸盐治疗对12个月romosozumab有效性的影响取决于既往治疗持续时间，这通过脊柱BMD百分比变化的差异反映出来（两者均< 0.05），然而，全髋骨密度变化百分比无显著差异结论罗莫珠单抗的疗效受既往治疗时间的影响。使用地舒单抗和口服双膦酸盐超过1年减弱了romosozumab的作用。
The effect of romosozumab is affected by previous osteoporosis treatment. Here we showed that the duration of the previous treatment just before romosozumab affects the therapeutic effect of romosozumab. Using denosumab and oral bisphosphonates for more than 1 year attenuates the effect of romosozumab.IntroductionAs an anti-sclerostin antibody, romosozumab suppresses bone resorption and stimulates bone formation. We investigated whether the effectiveness of 12 months of romosozumab treatment depended on the duration of previous treatment with teriparatide, denosumab, or oral bisphosphonates.MethodsIn total, 259 osteoporosis patients received subcutaneous injections of romosozumab (210 mg) every 4 weeks during 2019 and 2020. This study was designed as a pre–post comparison. The end points were the percent changes of bone mineral density (BMD) after 12 months of romosozumab treatment. The patients were divided into seven groups depending on the type and duration of previous treatment before starting romosozumab as follows: non-previous treatment group, change from teriparatide used for 1 year or less/more than 1 year, change from denosumab used for 1 year or less/more than 1 year, and change from oral bisphosphonates used for 1 year or less/more than 1 year.ResultsThe effects of previous treatment with teriparatide on the effectiveness of 12-month romosozumab did not clearly depend on the duration of treatment (p> 0.05). In contrast, the effects of previous treatments with denosumab or oral bisphosphonates on the effectiveness of 12-month romosozumab depended on the previous treatment duration, which was reflected by the differences in percent change of the spine BMD (bothp< 0.05), however, there were no significant differences in the percent change of the total hip BMD (bothp> 0.05).ConclusionThe duration of the previous treatment affected the effectiveness of romosozumab. Using denosumab and oral bisphosphonate for more than 1 year attenuated the effect of romosozumab.